Rick Holliday-Smith, then on the boards of Cochlear and ASX, was speaking at a small Sydney investment conference in late 2019 when he revealed his irritation about investors who refused to stick with promising medical companies.

“Most of the time, we sell at the sizzle stage because people don’t believe enough that the fat is going to follow ... it’s too risky,” he said.